Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
Chris HollenJessica RiceMichelle ParkVijayshree YadavPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
Case Summary: While multiple sclerosis (MS) disease activity declines during pregnancy, there are situations where MS relapses in pregnant women do occur. Mild relapses may be managed with close observation, but severe refractory relapses may require more aggressive management. We describe two cases of rituximab used for severe, refractory multiple sclerosis relapses during pregnancy. Rituximab did not appear to complicate either pregnancy and there were no further relapses for either women. Rituximab should not be overlooked in rare refractory cases, such as the rebound relapses sometimes seen following the discontinuation of lymphocyte-sequestering disease-modifying therapies.
Keyphrases
- multiple sclerosis
- diffuse large b cell lymphoma
- disease activity
- pregnant women
- rheumatoid arthritis
- white matter
- systemic lupus erythematosus
- hodgkin lymphoma
- chronic lymphocytic leukemia
- mass spectrometry
- pregnancy outcomes
- early onset
- type diabetes
- ms ms
- preterm birth
- peripheral blood
- rheumatoid arthritis patients
- drug induced